Medicinal products with the active ingredient Bimekizumab
Discount agreements for finished medicinal products with the active ingredient Bimekizumab (ATC: L04AC21): non-exclusive contracts under an open-house model, conclusion possible at any time with any qualified pharmaceutical company under the same conditions, no individual negotiations. Earliest contract start is 01.01.2027, maximum duration 24 months, contract ends on 31.12.2028. Contracts may be terminated if exclusive contracts are tendered. This is not a public contract under § 103 GWB.
Never miss a tender again
We send you 3 current matches that fit your company.
Tender documents
- Portal — LOT-0001NON-RESTRICTED-DOCUMENT
- TED HTML — 798136-2026HTML
- TED PDF — 798136-2026PDF
- TED XML — 798136-2026XML
Unlock documents for free
Enter your email address. If you confirm, we will also send you 3 similar tenders.